Analysts await BELLUS Health Inc (TSE:BLU) to reports earnings on March, 16. The stock decreased 1.71% or $0.03 on March 14, hitting $1.72. About 56,657 shares traded hands. BELLUS Health Inc (TSE:BLU) has risen 45.83% since August 6, 2015 and is uptrending. It has outperformed by 48.78% the S&P500.

BELLUS Health Inc. is engaged in developing drugs for rare diseases starting with conditions that affect the kidneys. The company has a market cap of $102.93 million. The Company’s lead program is KIACTA, a drug candidate in a Phase III Confirmatory Study for the treatment of AA amyloidosis, a rare disease resulting in renal dysfunction that often leads to dialysis and death. It has 403.76 P/E ratio. KIACTA is also being developed as a treatment in a second indication called sarcoidosis, a rare inflammatory condition that affects the lungs.

The post Analysis and BELLUS Health Inc (BLU) Earnings Review appeared first on Octafinance.